

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/766,030	01/29/2004	Alexander W. Oxford	620-888	1111
23117 7	590 03/03/2006		EXAMINER	
NIXON & VANDERHYE, PC			DENTZ, BERNARD I	
901 NORTH GLEBE ROAD, 11TH FLOOR ARLINGTON, VA 22203		OR	ART UNIT	PAPER NUMBER
			1625	1625

DATE MAILED: 03/03/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

+		Application No.	Applicant(s)			
•						
Office Action Summary		10/766,030	OXFORD ET AL.			
	· · · · · · · · · · · · · · · · · · ·	Examiner	Art Unit			
	The MAILING DATE of this communication of	Bernard Dentz	1625			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
2a) <u></u>	Responsive to communication(s) filed on 28 This action is FINAL . 2b) To Since this application is in condition for allow closed in accordance with the practice under	nis action is non-final. vance except for formal matters, pro				
Dispositi	on of Claims					
 4) Claim(s) 1-33 is/are pending in the application. 4a) Of the above claim(s) 1-17 and 25-27 is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) 18-24 and 28-33 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement. 						
Applicati	on Papers					
10)	The specification is objected to by the Exami The drawing(s) filed on is/are: a) a Applicant may not request that any objection to the Replacement drawing sheet(s) including the corre The oath or declaration is objected to by the	ccepted or b) objected to by the land displayments. See the drawing(s) be held in abeyance. See ection is required if the drawing(s) is objection.	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).			
Priority u	inder 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
2) Notice Notice Inform	e of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB/0 No(s)/Mail Date 4-27 & 8-24-04.	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Page 1990 6) Other:				

Application/Control Number: 10/766,030

Art Unit: 1625

In the restriction requirement of 9-29-2005 pharmaceutical composition claim 18 should have been placed in Gps. III and IV depending on whether the active ingredient contains N in the Y moiety.

The restriction requirement is repeated and made final for the reasons of record.

Applicants have elected Gp. IV with traverse. Claims 18-24 and 28-33 are under examination.

· Claims 18-24 and 28-33 are objected to for being drawn to a misjoinder of invention. The non-elected material should be canceled.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 18-24 and 28-33 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claim 19, line 3, before "chemically" "and" should be changed to - - or - -.

The compounds of Gp. IV are allowable in substance. If applicants were to limit the pharmaceutical claim to the exact scope of the allowable compounds it would be allowable.

If applicants would do the same in a pharmaceutical method claim, where the use were limited to a primary headache disorder, it would be allowable.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bernard Dentz whose telephone number is 571-272-0683. The examiner can normally be reached on Mon-Fri from 8 to 4:30.

Application/Control Number: 10/766,030

Art Unit: 1625

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang, can be reached on 571 272-0683. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Dentz

3-1-2006

BERNARD DENTZ PRIMARY EXAMINED Page 3